Editorial Comment
Heart-to-Heart New Approaches for Gene Transfer in the Myocardium Terrence X. O'Brien, MD; John J. Hunter, MD; Emily Dyson, MD; and Kenneth R. Chien, MD, PhD T he advent of molecular cloning has led to the rapid isolation, identification, and characterization of genes critical for the maintenance of normal contractile, conduction, and adaptive responses of the heart. Several studies have employed specific gene probes to precisely identify molecular defects in a variety of hereditary cardiovascular diseases such as familial hypercholesterolemia,' abetalipoproteinemia,2 and hypertrophic cardiomyopathy.3'4 Using a panel of gene probes to analyze qualitative and quantitative alterations in specific cardiac messenger RNAs, several investigators have delineated complex genetic responses during cardiac growth and hypertrophy that include the induction of proto-oncogenes and immediate early genes5-7 as well as the upregulation of constitutively See p 2007 expressed contractile protein genes8 and the activation of an embryonic gene program.8-10 (Techniques and terminology in cardiovascular molecular biology have recently been reviewed. 11) Complementing the rapid increase in well-characterized cardiac gene probes has been the development of gene transfer techniques, thereby allowing an assessment of the effects of this overexpression of a normal gene or expression of a mutant gene on cell structure, function, and physiology. To identify important functional domains of the encoded protein, normal and mutant gene constructs have been introduced into surrogate cells that have negligible basal expression of the gene of interest, and precise mapping of the gene sequences that dictate cardiacspecific and/or inducible expression during ventricular hypertrophy has been accomplished through the construction and expression of fusion genes consisting of cardiac promoters that drive the expression of a reporter gene such as luciferase.12-'7
The development of gene transfer techniques dates back to early studies in bacterial cells that used DNA from a bacterial virus (bacteriophage A) to introduce genes encoding proteins involved in galactose metabolism.18 These studies capitalized on the intrinsic ability of the bacteriophage A DNA to integrate into the genome of the E. coli bacteria and on the ability of the transferred gene to confer a genetic advantage to the host bacterial cells. Selection of the bacterial cells that have integrated the gene is initiated by placing the cells in a defined culture medium. 18 During the next several years after the development of this technique, the efficiency and spectrum of recipient cells, including mammalian cells,19 were greatly increased by the coprecipitation technique, in which the DNA of interest is precipitated with either calcium phosphate or a diethylaminoethyl-dextran polymer, a process referred to as "transfection." While it is hypothesized that the precipitated DNA enters the recipient cells by endocytosis and is subsequently transferred to the nucleus, the precise mode of entry and mechanisms of uptake are largely unknown. The efficiency of conventional transfection methods can be upwards of 20% in the most permissive cell lines, and the activity of the transfected gene can often be detected within 48 hours. Alternatively, by cotransfecting vectors that direct the expression of an antibiotic resistance gene, it is possible to select for mammalian cells that have stably integrated the transferred gene into chromosomal DNA, thereby resulting in clonal cell lines that stably express the gene of interest. Through the use of transfection procedures, the transient and stable expressions of cloned genes have become a standard tool in the arsenal of recombinant DNA technology. 20 Since the initial description of the successful transfection of foreign genes into cultured cardiac cells,12 a growing number of investigators have harnessed transfection and transient assays to study gene expression in these terminally differentiated muscle cells.8 [12] [13] [14] [15] [16] [17] To improve the efficiency of gene transfer, a number of alternatives to precipitation techniques have recently been developed. The encapsulation of the DNA of interest in artificial lipid membranes (liposomes) can result in a higher efficiency of gene transfer in certain cell types. 21 The liposomes subsequently fuse with the recipient cell membrane, thereby allowing entry of the DNA into cytoplasm and ultimately into the nucleus. Alternatively, the bombardment of cells with high-velocity tungsten microbeads coated with a plasmid DNA is also an effective technique for gene transfer in cardiac cells. 22 For achieving gene transfer in suspensions of cultured cells, electroporation of the DNA can be a particularly useful approach.23 Cells are exposed to high-voltage electric pulses that lead to the formation of nanometer-sized pores in the cell membranes. Depending on the cell line, electroporation can be a very effective technique, occasionally resulting in transient expression in 50% of the target cells. However, the viability of the cells can be compromised by electroporation, which might represent an important limitation in certain experimental applications. In general, when integration does occur, the cell line will carry one or more copies of the foreign DNA. Electroporation has recently been effectively used to examine sequences within the atrial natriuretic factor gene that regulate expression in primary cardiocyte cultures13 and to examine the regulated expression of cardiac myosin heavy chain genes in fetal rat cardiac myocytes during thyroid hormone stimulation. 24 A recent addition to the repertoire of gene transfer techniques has been the microinjection of genes into living cells. 25 Microinjection has been successfully used to rescue the genetic defect in dysgenic mouse muscle cells, which lack functional Ca21 channels. The single-needle microinjection of a wild-type calcium channel gene directly into the nucleus restores voltage-gated Ca21 channel activity and prevents the appearance of the dysgenic muscle cell phenotype. 26 The potential applications of single-cell microinjection have recently been expanded to include the injection of purified recombinant proteins, neutralizing antibodies, and competitor oligonucleotides, which have allowed a critical examination of the role of specific gene products in the acquisition of a variety of defined phenotypic features that can be assayed at the single-cell level. Although there have been several difficulties in extrapolating these results in nonmuscle cells to cardiac myocytes in culture, the successful adaptation of microinjection techniques to terminally differentiated living cardiac cells has remained an admirable goal. However, microinjection has already proven to be useful in elucidating the signaling pathways that mediate proliferation and differentiation in other cell types, and may be equally valuable in the study of cardiac cell physiology.
Although the transfection of foreign genes in cultured myocardial cells has provided insight into the control of cardiac gene expression, several of the most important and complex cardiovascular problems, such as atherogenesis, pressure overload-induced hypertrophy, and cardiac developmental ab-normalities, can only be fully reproduced in the in vivo state. Targeting the in vivo expression of exogenous genes in specific cell types has become one of the major challenges in the field of gene transfer and genetic therapy. Toward this goal, several investigators have developed novel approaches to achieve in vivo expression in the diverse cell types that constitute the heart and vascular system. In the past several months and in this issue, Circulation has published several articles in this arena. [27] [28] [29] [30] The intramuscular injection of plasmid DNA into skeletal muscle can result in the transient expression of the foreign gene in differentiated skeletal myotubes.31 These studies have recently been extended to the heart by two research groups.28,32 Injection of an expression vector into the exposed left ventricles of anesthetized, openchested rats can result in the expression of a 13-galactosidase reporter gene in a focal, patchy distribution for up to 4 weeks after the initial injection. 28 Although the unpredictability of cellular expression is a potential limitation, these results support the feasibility of in vivo transient expression studies in the heart.
In addition to approaches using the direct injection of naked DNA into intact muscle, Nabel and cowork-ers33 have used recombinant retroviruses that can yield a higher efficiency of expression of the foreign gene. Although initially utilized exclusively in cultured cells,34,35 viral vectors have recently been used for the expression of exogenous genes in vivo. A number of animal viruses have been engineered to serve as gene delivery systems, including retroviruses, adenoviruses, poxviruses, and herpesviruses. The vectors are based on the construction of replicationdeficient viruses that have been engineered to contain the foreign gene of interest. Although the recombinant virus contains the viral capsid proteins and maintains a normal portal of entry into the target cell, infection with the virus does not result in a cytopathic effect because of the deletion of viral genes critical to replication. The foreign gene is usually inserted at the site of the deletion. The virus can only be propagated in helper cell lines that have been stably transfected to constitutively express the deleted viral genes. In this manner, the gene of interest is inserted into the recombinant viral genome and the viral DNA is transfected into the helper cell lines, which results in the recovery of the recombinant virus in sufficient titers to infect the target cells of interest. By the use of high viral titers for infection, transient expression with adenoviral vectors can be driven to 100% efficiency in cultured cardiac cells.36 Using recombinant retroviral vectors, Nabel and coworkers33 demonstrated their efficacy in directing in vivo expression in the vascular wall. Alternatively, viruses can be used to stably integrate the genes of interest into endothelial and smooth muscle cells in culture, followed by their reseeding into the vascular wall in the in vivo setting. 35 These new approaches for in vivo expression are rapidly improving our repertoire of available technology to achieve expression in the in vivo state (for a review, see Reference 37) .
A major limitation to the generalized use of viral vectors has been the length of time required to generate each recombinant virus. If in vivo gene transfer could be achieved by conventional transfection procedures analogous to studies in cultured cells, in vivo expression studies would be greatly facilitated. Toward this end, two independent labo-ratories27,29 have documented the utility of liposomal lipofectin-based approaches to gene transfer in the vasculature in the in vivo setting. One of these laboratories is that of Lim et al,29 who report in this issue of Circulation gene transfer to both peripheral and coronary vessels. 29 The techniques are based on the development of catheter systems that allow the introduction of the DNA at appropriate sites in the peripheral or coronary vessel wall. Although the studies use different reporter genes to monitor expression (luciferase29 versus f-galactosidase27), there is a growing consensus that the transient transfer and assay of foreign genes are indeed feasible in both endothelial and smooth muscle cells in the peripheral and coronary arterial trees. Clearly, the ability to transiently express genes in the in vivo setting holds great promise for identifying the role of specific gene products in complex problems in cardiovascular biology and medicine.
The previously mentioned in vivo studies have primarily been aimed at introducing genes into somatic cells. In this case, the animals that express the foreign genes at specific tissue sites would not be capable of transmitting the foreign gene to their offspring, because the gene would not be integrated into the germ line cells. The manipulation of the genome in intact organisms to allow the hereditary transmission of the transferred gene is now possible through the generation of transgenic animals. Gene transfer is accomplished by the injection of the gene of interest into a fertilized ovum, followed by the implantation of the fertilized ovum in a pseudopregnant mouse. 38 Although the majority of the offspring will not integrate the transgene into their genome, several of the progeny will not only harbor the foreign gene but will also display positive expression. Of these founder mice, a proportion will then be capable of transmitting the transgene to their offspring. Through the use of cardiac-specific promoters, it is now possible to target expression of the transgene specifically in the atrium38 or the ventricle,39 with negligible expression in other noncardiac tissues. In this manner, transgenic models have already been of value in the examination of the consequences of the overexpression of a viral oncogene (SV40 large T antigen38 or the proto-oncogene c-myc39) on cardiac growth and development. Recently, new transgenic techniques have used totipotent embryonic stem cells that will also allow the ablation of specific genes. Capecchi40 has developed a system to inactivate specific target genes in embryonic stem cells by homologous recombination. By incorporating the embryonic stem cells into developing embryos, these investigators have generated progeny in which one of the alleles of interest has been inactivated. By mating the heterozygous mice, which contain the single inactivated allele, the production of mice homozygous for the deficiency of the target gene is now possible, thereby allowing a detailed examination of the effects of the complete loss of a specific gene product in the in vivo context of normal growth and development.
In short, a new wave of technology has been developed to express genes of interest into fully differentiated myocardial, skeletal, and smooth muscle cells as well as endothelial cells in both in vitro and in vivo model systems. Further advances in the generation of transgenic animals have been made that will allow specific target genes of interest to either be transmitted or ablated on a heritable basis. In the study of complex physiological responses, we are quickly moving beyond the simple identification and cloning of genes to the manipulation of genomes in intact organisms. As our capabilities to target the in vivo expression of foreign genes continue to progress, the phrase "heart-to-heart" may take on new meaning to molecular cardiologists.
